CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 602 enrolled
Drug / intervention
FluBlok Influenza Vaccination +1 morebiological
Likely dose
FluBlok Influenza Vaccination 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00539864
NCT00539864Phase 3Completed
CompareCT.gov

Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64

Protein Sciences Corporation·interventional·Posted Oct 5, 2007·Updated Jul 27, 2011

In Brief

A Phase 3 clinical trial evaluating FluBlok Influenza Vaccination and TIV (Fluzone) Influenza Vaccination for Influenza. Completed, enrolled 602 participants across 5 sites.

Detailed Summary

The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 5, 2007
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.7 years ago

Interventions

FluBlok Influenza Vaccinationbiological

0.5mL dose for intramuscular injection

TIV (Fluzone) Influenza Vaccinationbiological

0.5mL dose for intramuscular injection